Database→P21

Tier 4CognitiveNeuroprotectionAnti-agingPREMIUM

P21

P21 / P021 (Ac-DGGLAG-NH2) — CNTF-Derived Tetrapeptide Mimetic

Not FDA-approved. No IND filed as of profile date; Phanes Biotech (PB021) IND approval reported 2025, Phase 1 planned 2026. Research compound only.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

P21 (also designated P021, Ac-DGGLAG-NH2) is a synthetic tetrapeptide derived from amino acid residues 148 to 151 of ciliary neurotrophic factor (CNTF), with an adamantylated glycine C-terminal modification for blood-brain barrier penetration and oral bioavailability. Developed by Dr. Khalid Iqbal's group at the New York State Institute for Basic Research, P21 promotes hippocampal neurogenesis and upregulates BDNF by competitively inhibiting LIF/STAT3 signaling. It has shown cognitive rescue in aged rats and disease-modifying effects in 3xTg-AD transgenic mice. No human clinical trials have been conducted.

🔒

Full Profile: Premium Members Only

The complete P21 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use